Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 4

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 4
---
 is possible
to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production
of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing
technologies for critical drugs. To achieve these goals, we will aim to complete our initial business combination with one or more target
companies that can deliver a solution to (1) the lack of supply chain visibility into where and by whom critical drug products are
manufactured and (2) the inability to accurately predict and proactively relieve ongoing and future drug shortages.

2

We believe that we have an
important role in the future of the pharmaceutical business. With a successful series of target acquisitions the result will be a fully
integrated competitive cost business with vast expertise. The aim will be for this business to have end-to-end capability from plant-based
raw material production for a spectrum of controlled substances (the Active Pharmaceutical Ingredients (“API”)) to drug manufacturing
and prescriptions filled by pharmacies or directly to the patients.

The post-business combination
company would aim to grow revenues building on an addressable market for the $44 billion plant-based production segment, API market,
and generic medications. As a full spectrum producer, the finished product would allow the post-business combination company to disrupt
the current situation in the pharmaceutical market at a competitive cost while all operation from beginning of a product life-cycle
to its end-user application are made in America. The complete solution will aim to provide supply chain resilience while mitigating identified
national health and security risks.

We believe that the deliverable
of the post-business combination company over a lifecycle from seed to the finished generic drug, delivered to the pharmacy or patient
directly, could mitigate an identified national security risk. The business model will seek to guarantee production serviced by clean
advanced technology leveraging artificial intelligence in controlled environments that are premised on advanced production technology
in an energy efficient manner, while developing new continuous manufacturing processes for critical drugs and active pharmaceutical ingredients.

Shortages of critical medications
continue to rise — including drugs used in hospital emergency rooms and to treat cancer, prescription medications, and
even common over-the-counter treatments like children’s cold and flu medicine. Drug shortages are not a new problem. They are caused
by a number of factors, including economic drivers, insufficient supply chain visibility, and a continued U.S. overreliance on both
foreign and geographically concentrated sources for medications and their